WP
ACAD icon

Woodline Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Woodline Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-676,401
Closed -$15.1M – 1013
2026
Q1 		$15.1M Buy
+676,401
New +$16.2M 0.06% 403
2025
Q4 		– Sell
-151,453
Closed -$3.23M – 1011
2025
Q3 		$3.23M Sell
151,453
-685,746
-82% -$16.2M 0.02% 654
2025
Q2 		$18.1M Buy
837,199
+541,989
+184% +$10.1M 0.1% 309
2025
Q1 		$4.9M Buy
295,210
+268,445
+1,003% +$4.88M 0.03% 515
2024
Q4 		$491K Buy
+26,765
New +$432K ﹤0.01% 836
2024
Q1 		– Sell
-474,159
Closed -$14.8M – 530
2023
Q4 		$14.8M Buy
+474,159
New +$11.3M 0.16% 185
2023
Q3 		– Sell
-830,355
Closed -$19.9M – 582
2023
Q2 		$19.9M Buy
830,355
+399,450
+93% +$8.88M 0.24% 126
2023
Q1 		$8.11M Buy
+430,905
New +$8.21M 0.11% 227
2022
Q4 		– Sell
-395,549
Closed -$6.47M – 746
2022
Q3 		$6.47M Buy
395,549
+135,582
+52% +$2.2M 0.09% 253
2022
Q2 		$3.66M Buy
+259,967
New +$4.85M 0.06% 304
2022
Q1 		– Sell
-416,200
Closed -$9.71M – 711
2021
Q4 		$9.71M Sell
416,200
-172,659
-29% -$3.47M 0.14% 204
2021
Q3 		$9.78M Sell
588,859
-74,195
-11% -$1.43M 0.16% 166
2021
Q2 		$16.2M Buy
663,054
+272,463
+70% +$6.15M 0.3% 88
2021
Q1 		$10.1M Buy
390,591
+339,678
+667% +$15M 0.22% 116
2020
Q4 		$2.72M Sell
50,913
-276,502
-84% -$13.7M 0.07% 184
2020
Q3 		$13.5M Buy
327,415
+265,840
+432% +$11.5M 0.44% 68
2020
Q2 		$2.98M Buy
+61,575
New +$2.96M 0.12% 128

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Woodline Partners's ACAD Position: Q2 2026 in Review

Woodline Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 676,401 shares — an estimated $15.1M sold.

Woodline Partners first reported a position in ACAD in Q2 2020 and held it in 17 quarters. The position peaked at $19.9M in Q2 2023. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Woodline Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 676,401 Acadia Pharmaceuticals shares in Q2 2026, an estimated $15.1M.
  • Woodline Partners first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 17 quarters.
  • Woodline Partners's Acadia Pharmaceuticals position peaked at $19.9M in Q2 2023.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.